Phase 1 development of Axl, Mer, CSF1R inhibitor Q702

Qurient Co., Ltd.

Qurient Therapeutics

IMMUNOLOGY | **Phase 1**

Product Type	Small molecules
Indication	Chronic graft versus host disease (cGVHD)
Target	Axl, Mer, CSF1R
MoA(Mechanism of Action)	• cGVHD is a significant complication following an allogeneic stem cell or bone marrow transplant • Median onset of cGVHD is 6 months following transplant. Average treatment duration of 1-3 years • Fibrosis constitutes the end stage of the inflammatory process in cGVHD leading to major morbidity • Although AXL, Mer, CSF1R signals are reported to be involved in cGVHD, CSF1R signaling is a key regulator of fibrosis-mediating macrophages.
Competitiveness	
Development Stage	Phase 1
Route of Administration	Oral Administration

	Q702 (Adrixetinib) Axl, Mer, CSF1R inhibitor
Target Inhibition	• Comparable biological effect in human to Axatilimab
Clinical Benefits	• Additional benefits through multi-target inhibition • Axl, Mer inhibition provides additional anti-fibrosis activity • Axl inhibition provides prophylactic anti-leukemia activity for potential relapse
Patient Convenience	• Orally administered, allowing easy dose modification for safety management.
Accessibility	• Self-administration possible • Suitable for various patient body weights • Flexible combination with other therapeutic agents